Technical Data
045156
PJ-34 (N-(6-Oxo-5,6-dihydro-phenanthridin-2-yl)-N,N-dimethylacetamide . HCl)
1mg
Biochemicals Storage: +4C/+4CShipping: Blue Ice
Potent, water soluble poly(ADP-ribose) polymerase (PARP) inhibitor. Inhibits peroxynitrite-induced cell necrosis. Shows significant, dose-dependent anti-inflammatory effects in a variety of local inflammation models. Provides cardioprotection by decreasing myocardial infarct size. Shows protective effects in models of stroke. Suppresses cell growth in liver cancer cells.

Storage and Stability:
Short-term Storage: +4C
Long-term Storage: +4C
Stable for at least 2 years after receipt when stored at +4C.

CAS Number:
344458-15-7

Molecular Formula:
C17H17N3O2 . HCl

Molecular Weight:
295.2+36.5
Purity: >98% (NMR)

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference:
Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation: F. Garcia Soriano, et al.; Nat. Med. 7, 108 (2001)
Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke: G.E. Abdelkarim, et al.; Int. J. Mol. Med. 7, 255 (2001)
Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase: J.G. Mabley, et al.; Inflamm. Res. 50, 561 (2001)
Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure: P. Pacher, et al.; J. Am. Coll. Cardiol. 40, 1006 (2002)
Novel phenanthridinone inhibitors of poly (adenosine 5'-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents: P. Jagtap, et al.; Crit. Care Med. 30, 1071 (2002)
Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor: R. Faro, et al.; Ann. Thorac. Surg. 73, 575 (2002)
PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells: Oncol. Rep. 20, 567 (2008)
The role of PARP activation in glutamate-induced necroptosis in HT-22 cells: X. Xu, et al.; Brain Res. 1343, 206 (2010)
Renal hypoperfusion and impaired endothelium-dependent vasodilation in an animal model of VILI: the role of the peroxynitrite-PARP pathway: R. Vaschetto, et al.; Crit. Care 14, R45 (2010)


Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.